Skip to content
Hope Rugo· @hoperugo · X·· 1 day agoScore70

AKT

Body · original

Peter Fasching summarizes the topics in HR+ disease from the first 3 talks in proffered session 2 @myesmo @OncoAlert #ESMO2026

317 views · 14 likes · 7 reposts · 1 reply

Conference abstracts
2220RONCT04746300matched by Rapid oral: Genitourinary tumours, prostate, penile and testis

Plasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)

https://esmocongress.esmo.org
Replies in this thread
  1. Ziad Storyteller@AIZiadSaliba

    @hoperugo @myESMO @OncoAlert What stands out to me is the move from single-pathway targeting to rational combinations, CDK4/6 with PI3K or AKT inhibition guided by ctDNA. Sequencing by clonal dynamics rather than line of therapy is where HR+ disease is heading #ESMO2026

Source: Hope Rugo · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org